Skip to main content
. Author manuscript; available in PMC: 2014 Aug 26.
Published in final edited form as: AIDS. 2012 Nov 13;26(17):2185–2192. doi: 10.1097/QAD.0b013e328359f255

Table 4.

Risk of anal intraepithelial neoplasia grade 2 and anal intraepithelial neoplasia grade 3 according to combinations of mRNA, p16/Ki-67, and HPV16/18 DNA.

Test combination No dysplasia AIN1 AIN2 AIN3 Total
mRNA+/p16/Ki-67+/16/18+ 12 (12.50%) 25 (26.04%) 25 (26.04%) 34 (35.42%) 96
mRNA+/p16/Ki-67+/16/18− 16 (33.33%) 11 (22.92%) 11 (22.92%) 10 (20.83%) 48
mRNA+/p16/Ki-67−/16/18+ 3 (33.33%) 5 (55.56%) 0 (0%) 1 (11.11%) 9
mRNA+/p16/Ki-67−/16/18− 5 (50.0%) 3 (30.0%) 1 (10.0%) 1 (10.0%) 10
mRNA−/p16/Ki-67+/16/18+ 2 (28.57%) 2 (28.57%) 2 (28.57%) 1 (14.29%) 7
mRNA−/p16/Ki-67+/16/18− 26 (40.63%) 25 (39.06%) 5 (7.81%) 8 (12.50%) 64
mRNA−/p16/Ki-67−/16/18+ 2 (25.0%) 4 (50%) 1 (12.50%) 1 (12.50%) 8
mRNA−/p16/Ki-67−/16/18− 61 (81.33%) 11 (14.67%) 2 (2.67%) 1 (1.33%) 75

Combined disease endpoints: no dysplasia, including men with a nondysplastic biopsy or without a biopsy and with <HSIL cytology; AIN1, including men with AIN1 histology and <HSIL cytology; AIN2, including men with AIN2 histology or with lower grade, normal, or no histology and with HSIL-AIN2; AIN3, including men with AIN3 histology or with lower grade, normal, or no histology and with HSIL-AIN3. AIN1, anal intraepithelial neoplasia grade 1; AIN2, anal intraepithelial neoplasia grade 2; AIN3, anal intraepithelial neoplasia grade 3; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion.